SHIM
ADIL

Stone House Investment Management’s Adial Pharmaceuticals ADIL Stock Holding History

Stone House Investment Management’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-108
Closed -$816 – 723
2025
Q2 		$816 Buy
+108
New +$1.63K ﹤0.01% 473

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Stone House Investment Management's ADIL Position: Q3 2025 in Review

Stone House Investment Management sold out of Adial Pharmaceuticals (ADIL) in Q3 2025, closing a stake of 108 shares — an estimated $816 sold.

Stone House Investment Management first reported a position in ADIL in Q2 2025 and held it in 1 quarter. The position peaked at $816 in Q2 2025. 15 funds tracked by Wall St. Rank hold ADIL as of Q3 2025.

  • Stone House Investment Management reported no remaining Adial Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Stone House Investment Management sold 108 Adial Pharmaceuticals shares in Q3 2025, an estimated $816.
  • Stone House Investment Management first reported a position in Adial Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Stone House Investment Management's Adial Pharmaceuticals position peaked at $816 in Q2 2025.
  • 15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2025.

Based on Stone House Investment Management's 13F filing for Q3 2025, filed 27 Oct 2025.